Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | C7R.CD30.CAR-EBVS T-cells |
| Synonyms | |
| Therapy Description |
C7R.CD30.CAR-EBVS T-cells are allogeneic Epstein Barr virus-specific T-cells (EBVSTs) engineered to express a chimeric antigen receptor (CAR) recognizing CD30, IL7R, and an inducible caspase 9 (iC9), which potentially inhibits tumor growth (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| C7R.CD30.CAR-EBVS T-cells | C7R.CD30.CAR-EBVST cells | CD30 (TNFRSF8) Immune Cell Therapy 5 | C7R.CD30.CAR-EBVS T-cells are allogeneic Epstein Barr virus-specific T-cells (EBVSTs) engineered to express a chimeric antigen receptor (CAR) recognizing CD30, IL7R, and an inducible caspase 9 (iC9), which potentially inhibits tumor growth (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06176690 | Phase I | C7R.CD30.CAR-EBVS T-cells | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (CABAL2) | Recruiting | USA | 0 |
| NCT07729397 | Phase I | C7R.CD30.CAR-EBVS T-cells | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) (ANCILE-30) | Not yet recruiting | USA | 0 |